LONDON--(BUSINESS WIRE)--Acrongenomics, Inc. (OTCBB:AGNM - News) are pleased to update the current status of their main project, its involvement with Molecular Vision Limited. The Company is in discussions with two major European medical device companies with the intention that these companies participate as strategic investors in Acrongenomics. If these discussions end with positive results, the synergies between Acrongenomics and Molecular Vision would increase, and Acrongenomics would be in a better position to assist Molecular Vision towards achieving its business plan for the next two years. As matters progress, Acrongenomics will provide further updates and announcements.
